A two year, parallel, two group, open-label, real-world randomised controlled trial (RCT)
design for subjects with severe and complex obesity who are referred to a Tier 3 or
equivalent specialist weight management/obesity service. Participants will be randomised to
receive 1) standard care (obesity-specialist care), or 2) targeted prescribing pathway
(obesity-specialist care plus targeted use of Liraglutide 3.0mg [LIRA 3mg] with pre-specified
stopping rules for the medication). The aim of the study is to compare the effectiveness,
budget impact, and cost-effectiveness between the two groups in a real-world setting among
otherwise largely unselected patients.